Patents Assigned to Tris Pharma, Inc.
-
Patent number: 8778390Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.Type: GrantFiled: September 3, 2013Date of Patent: July 15, 2014Assignee: TRIS Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu, Ashok Perumal
-
Patent number: 8747902Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.Type: GrantFiled: October 29, 2013Date of Patent: June 10, 2014Assignee: TRIS Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Publication number: 20140127306Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.Type: ApplicationFiled: January 15, 2014Publication date: May 8, 2014Applicant: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Publication number: 20140093578Abstract: An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.Type: ApplicationFiled: November 26, 2013Publication date: April 3, 2014Applicant: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Publication number: 20140056984Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.Type: ApplicationFiled: October 29, 2013Publication date: February 27, 2014Applicant: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Publication number: 20140030334Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described.Type: ApplicationFiled: October 2, 2013Publication date: January 30, 2014Applicant: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8623409Abstract: An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.Type: GrantFiled: October 20, 2010Date of Patent: January 7, 2014Assignee: Tris Pharma Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Publication number: 20140004160Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.Type: ApplicationFiled: September 3, 2013Publication date: January 2, 2014Applicant: Tris Pharma Inc.Inventors: Ketan Mehta, Yu-Hsing Tu, Ashok Perumal
-
Patent number: 8597684Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described.Type: GrantFiled: January 22, 2013Date of Patent: December 3, 2013Assignee: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8563033Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate—ion exchange resin complex, a barrier coated methylphenidate—ion exchange resin complex—matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.Type: GrantFiled: May 30, 2013Date of Patent: October 22, 2013Assignee: Tris Pharma Inc.Inventors: Ketan Mehta, Yu-Hsing Tu, Ashok Perumal
-
Patent number: 8512688Abstract: A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations.Type: GrantFiled: September 12, 2012Date of Patent: August 20, 2013Assignee: Tris Pharma Inc.Inventors: Ketan Mehta, Yu-Hsing Tu, Mahendra Shah
-
Patent number: 8491935Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.Type: GrantFiled: November 1, 2012Date of Patent: July 23, 2013Assignee: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8465765Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.Type: GrantFiled: September 12, 2012Date of Patent: June 18, 2013Assignee: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu, Ashok Perumal
-
Publication number: 20130136797Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described.Type: ApplicationFiled: January 22, 2013Publication date: May 30, 2013Applicant: TRIS PHARMA, INC.Inventor: TRIS PHARMA, INC.
-
Publication number: 20130059007Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.Type: ApplicationFiled: November 1, 2012Publication date: March 7, 2013Applicant: TRIS PHARMA, INC.Inventor: Tris Pharma. Inc.
-
Publication number: 20130004452Abstract: A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations.Type: ApplicationFiled: September 12, 2012Publication date: January 3, 2013Applicant: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu, Mahendra Shah
-
Publication number: 20130004571Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.Type: ApplicationFiled: September 12, 2012Publication date: January 3, 2013Applicant: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu, Ashok Perumal
-
Patent number: 8337890Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.Type: GrantFiled: March 12, 2010Date of Patent: December 25, 2012Assignee: Tris Pharma IncInventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8287848Abstract: A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations.Type: GrantFiled: September 27, 2007Date of Patent: October 16, 2012Assignee: Tris Pharma IncInventors: Ketan Mehta, Yu-Hsing Tu, Mahendra Shah
-
Patent number: 8287903Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.Type: GrantFiled: September 26, 2011Date of Patent: October 16, 2012Assignee: Tris Pharma IncInventors: Ketan Mehta, Yu-Hsing Tu, Ashok Perumal